NuPathe Inc. (PATH) CEO to Ring The NASDAQ Stock Market Opening Bell

ADVISORY, Sept. 15, 2011 (GLOBE NEWSWIRE) --

What:

NuPathe Inc. (PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, will visit the NASDAQ MarketSite in New York City's Times Square.

In honor of the occasion, Jane Hollingsworth, CEO and an original founder of NuPathe, will ring the Opening Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Friday, September 16th, 2011 – 9:15 a.m. to 9:30 a.m. ET         

Contact:

Tiberend Strategic Advisors, Inc.

(212) 827-0020

Jason Rando

jrando@tiberend.com

Andrew Mielach

amielach@tiberend.com

NASDAQ MarketSite:

Jen Knapp

(212) 401-8916

Jennifer.knapp@nasdaqomx.com

Feed Information:

The Opening Bell is available from 9:20 a.m. to 9:35 a.m. on AMC3 / C20, downlink frequency 4100 vertical. The feed can also be found on Ascent fiber 1623. If you have any questions, please contact Jen Knapp at (212) 401-8916.

Facebook and Twitter:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page at:

http://www.facebook.com/nasdaqomx                                  

For news tweets, please visit our Twitter page at:

http://twitter.com/nasdaqomx

Webcast:

A live webcast of the NASDAQ Opening Bell will be available at:

http://www.nasdaq.com/about/marketsitetowervideo.asx or http://social.nasdaqomx.com.

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About NuPathe Inc. (PATH):

NuPathe Inc. (www.nupathe.com) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, the migraine patch (NP101 or Zelrix), is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to the migraine patch, NuPathe has two additional proprietary product candidates: NP201 for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and NP202 in preclinical development for the long-term treatment of schizophrenia and bipolar disorder.

About NASDAQ OMX:

The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with more than 3,500 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX first North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook (http://www.facebook.com/pages/NASDAQ-OMX/108167527653) and Twitter (http://www.twitter.com/nasdaqomx). 

NDAQA

In This Story

NDAQ